CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
BTK Inhibitors
Li ZhimingSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the BTK Inhibitors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Li Zhiming | Phase 2 | CCC |
Zanubrutinib Li Zhiming | Phase 2 | CCC |
Tucidinostat Li Zhiming | Phase 2 | CCC |
Cyclophosphamide Li Zhiming | Phase 2 | CCC |
VINDESINE Zhejiang Cancer Hospital | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →